Literature DB >> 14569466

Increased expression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma.

S Samantaray1, R Sharma, T K Chattopadhyaya, S Datta Gupta, R Ralhan.   

Abstract

PURPOSE: Matrix metalloproteinases (MMPs) are known to play an important role in extracellular matrix remodeling during the process of tumor invasion and metastasis. However, little is known about their role in preinvasive lesions and early esophageal carcinomas.
METHOD: Immunohistochemical analysis of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) expression was carried out in paraffin-embedded sections of surgically resected esophageal squamous cell carcinoma (ESCC) (58 cases) and paired distal normal esophageal tissues (44 cases) and correlated with clinicopathological parameters. RESULT: Overexpression of MMP-2 and MMP-9 proteins was observed in 39 (67%) and 32 (55%) of the 58 ESCCs, respectively localized in tumor cell cytoplasm and stromal elements. Histological evaluation of hematoxylin- and eosin-stained 44 matched distal normal esophageal tissue sections revealed that 26 comprised of normal epithelium, while 15 tissues showed evidence of dysplasia and three tissues showed hyperplasia. Interestingly, 12 (80%) and 13 (87%) of these 15 dysplasias showed immunostaining for MMP-2 and MMP-9 proteins, respectively. Low levels of MMP-2 and MMP-9 were observed in 10 (38%) and 6 (23%) of 26 matched histologically normal esophageal tissues, respectively. Higher MMP-2 immunopositivity was observed in well and moderately differentiated SCCs in comparison with poorly differentiated tumors. The expression of MMP-2 was significantly reduced with the progressive de-differentiation of esophageal SCCs ( P =0.03). Overexpression of MMP-2 and MMP-9 in dysplasia as well as SCC suggests that these alterations occur in early stages of esophageal tumorigenesis.
CONCLUSION: Increased levels of MMP-2 and MMP-9 proteins in ESCCs as compared to normal esophageal tissues suggest their association with esophageal tumorigenesis. Increased levels of these MMPs are observed in majority of dysplasias analyzed herein, indicating that these alterations may be early events in esophageal tumorigenesis. In-depth studies are warranted to determine their role in development and progression of esophageal cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14569466     DOI: 10.1007/s00432-003-0500-4

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  34 in total

1.  Cancer statistics, 1999.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1999 Jan-Feb       Impact factor: 508.702

2.  The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis.

Authors:  M D Sternlicht; A Lochter; C J Sympson; B Huey; J P Rougier; J W Gray; D Pinkel; M J Bissell; Z Werb
Journal:  Cell       Date:  1999-07-23       Impact factor: 41.582

Review 3.  Matrix metalloproteinases in human melanoma.

Authors:  U B Hofmann; J R Westphal; G N Van Muijen; D J Ruiter
Journal:  J Invest Dermatol       Date:  2000-09       Impact factor: 8.551

4.  Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3).

Authors:  H R Lijnen; F Ugwu; A Bini; D Collen
Journal:  Biochemistry       Date:  1998-04-07       Impact factor: 3.162

5.  Matrix metalloproteinases and their inhibitors in gastric cancer.

Authors:  G I Murray; M E Duncan; E Arbuckle; W T Melvin; J E Fothergill
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

6.  Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion.

Authors:  B Davies; J Waxman; H Wasan; P Abel; G Williams; T Krausz; D Neal; D Thomas; A Hanby; F Balkwill
Journal:  Cancer Res       Date:  1993-11-15       Impact factor: 12.701

7.  Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behavior of esophageal carcinoma. A clinicopathologic study.

Authors:  I Shima; Y Sasaguri; J Kusukawa; H Yamana; H Fujita; T Kakegawa; M Morimatsu
Journal:  Cancer       Date:  1992-12-15       Impact factor: 6.860

8.  Role of matrix metalloproteinase-9 in in vitro invasion of esophageal carcinoma cells.

Authors:  Tomotaka Suzuki; Yoshiyuki Kuwabara; Hiroji Iwata; Masami Mitani; Noriyuki Shinoda; Atsushi Sato; Akira Mitsui; Masahiko Sugiura; Joji Kato; Yoshitaka Fujii
Journal:  J Surg Oncol       Date:  2002-10       Impact factor: 3.454

9.  Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer.

Authors:  A G Remacle; A Noël; C Duggan; E McDermott; N O'Higgins; J M Foidart; M J Duffy
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

10.  The clinical significance of MMP-1 expression in oesophageal carcinoma.

Authors:  K Yamashita; M Mori; A Kataoka; H Inoue; K Sugimachi
Journal:  Br J Cancer       Date:  2001-01       Impact factor: 7.640

View more
  39 in total

1.  Towards the molecular characterization of disease: comparison of molecular and histological analysis of esophageal epithelia.

Authors:  Daniel Vallböhmer; Paul Marjoram; Hidekazu Kuramochi; Daisuke Shimizu; Hsuan Jung; Steve R DeMeester; Daniel Oh; Parakrama T Chandrasoma; Kathleen D Danenberg; Tom R DeMeester; Peter V Danenberg; Jeffrey H Peters
Journal:  J Gastrointest Surg       Date:  2007-09       Impact factor: 3.452

2.  Alterations of glutathione S-transferase and matrix metalloproteinase-9 expressions are early events in esophageal carcinogenesis.

Authors:  Laszlo Herszenyi; Istvan Hritz; Istvan Pregun; Ferenc Sipos; Mark Juhasz; Bela Molnar; Zsolt Tulassay
Journal:  World J Gastroenterol       Date:  2007-02-07       Impact factor: 5.742

3.  Guest-release control in enzyme-sensitive, amphiphilic-dendrimer-based nanoparticles through photochemical crosslinking.

Authors:  Krishna R Raghupathi; Malar A Azagarsamy; S Thayumanavan
Journal:  Chemistry       Date:  2011-09-02       Impact factor: 5.236

4.  Single-nucleotide polymorphisms of matrix metalloproteinases and their inhibitors in gastrointestinal cancer.

Authors:  Alexandra Mj Langers; Hein W Verspaget; Daniel W Hommes; Cornelis Fm Sier
Journal:  World J Gastrointest Oncol       Date:  2011-06-15

5.  BMP7 expression in esophageal squamous cell carcinoma and its potential role in modulating metastasis.

Authors:  Guanghui Xu; Shanhong Tang; Jianjun Yang; Kang Chen; Jianqin Kang; Guohong Zhao; Fan Feng; Xuewen Yang; Lina Zhao; Qun Lu; Li Sun; Liu Hong; Taiqian Gong; Hongwei Zhang
Journal:  Dig Dis Sci       Date:  2013-03-17       Impact factor: 3.199

6.  Transgenic mouse lines subdivide external segment of the globus pallidus (GPe) neurons and reveal distinct GPe output pathways.

Authors:  Kevin J Mastro; Rachel S Bouchard; Hiromi A K Holt; Aryn H Gittis
Journal:  J Neurosci       Date:  2014-02-05       Impact factor: 6.167

7.  Silencing of CXCR2 and CXCR7 protects against esophageal cancer.

Authors:  Kai Wu; Lingling Cui; Yang Yang; Jia Zhao; Dengyan Zhu; Donglei Liu; Chunyang Zhang; Yu Qi; Xiangnan Li; Weihao Li; Song Zhao
Journal:  Am J Transl Res       Date:  2016-08-15       Impact factor: 4.060

8.  MMP-2 and DcR3 expression in esophageal cancer tissue and correlation with patient survival.

Authors:  Ran Ao; Ya-Qi Du; Ying Wang; Yu-Shuai Chen; Bing-Yuan Wang
Journal:  Int J Clin Exp Med       Date:  2013-09-01

9.  Integrative and comparative genomics analysis of early hepatocellular carcinoma differentiated from liver regeneration in young and old.

Authors:  Dilek Colak; Muhammad A Chishti; Al-Bandary Al-Bakheet; Ahmed Al-Qahtani; Mohamed M Shoukri; Malcolm H Goyns; Pinar T Ozand; John Quackenbush; Ben H Park; Namik Kaya
Journal:  Mol Cancer       Date:  2010-06-12       Impact factor: 27.401

10.  Increased matrix metalloproteinase activation in esophageal squamous cell carcinoma.

Authors:  Sumana Mukherjee; Mark J Roth; Sanford M Dawsey; Wusheng Yan; Jaime Rodriguez-Canales; Heidi S Erickson; Nan Hu; Alisa M Goldstein; Philip R Taylor; Annely M Richardson; Michael A Tangrea; Rodrigo F Chuaqui; Michael R Emmert-Buck
Journal:  J Transl Med       Date:  2010-10-05       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.